Aperio Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Aperio Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$6.54M	Buy	89,365 +5,888	+7%	+$438K	0.02%	717
2020 Q3	$6.49M	Buy	83,477 +19,086	+30%	+$1.31M	0.02%	649
2020 Q2	$3.58M	Sell	64,391 -6,136	-9%	-$263K	0.01%	861
2020 Q1	$2.09M	Buy	70,527 +27,552	+64%	+$932K	0.01%	998
2019 Q4	$1.56M	Buy	42,975 +40	+0.1%	+$1.23K	0.01%	1206
2019 Q3	$1.17M	Buy	42,935 +6,868	+19%	+$178K	﹤0.01%	1316
2019 Q2	$868K	Buy	36,067 +676	+2%	+$17.1K	﹤0.01%	1473
2019 Q1	$935K	Buy	35,391 +9,743	+38%	+$231K	﹤0.01%	1398
2018 Q4	$501K	Buy	25,648 +7,360	+40%	+$144K	﹤0.01%	1677
2018 Q3	$358K	Buy	18,288 +1,873	+11%	+$35.6K	﹤0.01%	1934
2018 Q2	$272K	Buy	+16,415	New	+$250K	﹤0.01%	2038

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's HZNP Position: Q4 2020 in Review

Aperio Group increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 7.1% in Q4 2020, buying an estimated $438K and bringing the position to 89,365 shares worth $6.54M. The position accounts for 0.02% of the portfolio, ranked #717.

Aperio Group first reported a position in HZNP in Q2 2018 and has held it in 11 quarters since. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

Aperio Group held 89,365 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $6.54M as of Q4 2020.
Aperio Group bought 5,888 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $438K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.02% of Aperio Group's portfolio in Q4 2020, its #717 holding.
Aperio Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2018 and has held it in 11 quarters since.
497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.